



Toripalimab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

Medicine type	Biological agent
EML status history	Application rejected in 2023 (TRS 1049) for Malignant neoplasms of nasopharynx Application rejected in 2023 (TRS 1049) for Malignant neoplasms of oesophagus
Wikipedia	Toripalimab 
DrugBank	Toripalimab 

Recommendations

Section Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Malignant neoplasms of nasopharynx

Malignant neoplasms of oesophagus

